Goldman Sachs Upgrades Bristol-Myers Squibb Co. (BMY) to Conviction Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Bristol Myers Squibb (BMY) Receives Positive CHMP Opinion for Inrebic for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
December 11, 2020 7:15 AM ESTBristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Inrebic® (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential... More
Bristol-Myers Squibb (BMY) Announces Settlement of U.S. Patent Litigation for REVLIMID with Cipla
December 11, 2020 6:59 AM ESTBristol Myers Squibb (NYSE:... More
